Lancet oncology的問題，透過圖書和論文來找解法和答案更準確安心。 我們找到下列包括賽程、直播線上看和比分戰績懶人包

Textbook of Liver Transplantation: A Multidisciplinary Approach

為了解決Lancet oncology的問題，作者 這樣論述：

Patrizia Burra is Full Professor of Gastroenterology and Head of the Multivisceral Transplant Unit, Department of Surgery, Oncology and Gastroenterology at the University of Padua, Italy. Since 2015 she is ViceRector on Research Training at Padua University. Following the medical degree and the Dipl

oma on Gastroenterology and Endoscopy, she spent 3 years as research fellow at Queen Elizabeth Hospital in Birmingham, UK, before completing the PhD in Hepatology at the University of Padua. Patrizia Burra is interested in clinical and translational studies in the setting of liver transplantation, m

ainly regarding antiviral therapy for HCV recurrence, HBV prophylaxis after transplantation, acute alcoholic hepatitis as early indication for liver transplantation, liver transplantation for NASH and NAFLD, adherence to medical treatments and quality of life of transplant recipients.She has previou

sly served as President of ELITA, Vice President of ESOT, Chair of ILTS Education Committee, Treasurer of ILTS and ILTS President. She served EASL for 5 years, as EU Policy Councilor until 2016. Currently she is the elected Chair of the Public Affairs Committee 2022-2025 at United European Gastroent

erology (UEG). In 2021 she has obtained the Fellow of the American Association for the Study of Liver Diseases (FAASLD). She is also President of the NGO Marina Minnaja Foundation for the research and study of liver transplantation.Currently she is Co-chair of The Lancet - EASL Commission on liver d

iseases in Europe from 2018, Deputy Editor of Journal of Hepatology from 2019 and Associate Editor of Transplant International and Digestive and Liver Disease.She has authored over 340 articles in international peer-reviewed journals, with an H-index of 54 and over 1000 presentations in national and

international congresses.

Practical Medical Oncology Textbook

為了解決Lancet oncology的問題，作者 這樣論述：

Antonio Russo is Full Professor of Medical Oncology at the University of Palermo (Italy). He is head of the Medical Oncology Unit and of the Reference Center of Rare and Heredo-familial Solid Tumors, Palermo (Italy). In addition, he is Coordinator of the PhD in Oncology at the University of Palermo

and Adjunct Full Professor at Temple University’s, Philadelphia (USA). He is a medical oncologist and he focuses on translational oncology, hereditary, rare, lung, gastrointestinal and ovarian cancers. Previously he was Director of the Specialization School in Medical Oncology, University of Palermo

. He was co-chair of the ＂CRCP53 International Collaborative Study＂ project and also member of the international RASCAL II project group. He is an active member of the main scientific oncological groups as ASCO, ESMO, ISBL and AIOM, of which he is a member of the national board of councillors. He wa

s an expert member of INSERM (France), of the Scientific Committee INCA (France) and of the NWCRF (UK). Recently, he has been the recipient of numerous professional accolades, including a Visiting Professor and an Honorary Professor membership for the Peruvian Ricardo Palma University. In 2019 he al

so received the prestigious NIAF Award for Ethics and creativity in Medical research in Washington (USA). He is the author of more than 300 peer-reviewed publications listed on Medline-PubMed including Journal of Clinical Oncology, Lancet, Annals of Oncology, Oncoimmunology, Lancet Oncology, Oncolog

ist, Cell Stem Cell. He is actually a member of the Editorial board of the high-indexed ＂Cancers＂ journal and guest editor for ＂Cancers＂ and ＂Frontiers in Oncology＂. Lastly, he is Editor-in-Chief of several academic textbooks in oncology for Springer Nature. Marc Peeters is a Professor of Oncology a

t Antwerp University, Belgium. He is head of the oncology department at Antwerp University Hospital and coordinator of the Multidisciplinary Oncology Center Antwerp. He is also chairman of the College of Oncology. Previously, he was Coordinator of the Digestive Oncology Unit at the University Hospit

al in Ghent, Belgium. He completed his medical studies at the Catholic University in Leuven, Belgium. He underwent additional training in Oncology and Digestive Oncology at the UZ Gasthuisberg, the Institut Gustave Roussy in Villejuif, Paris, the University of Pennsylvania Hospital in Philadelphia,

the Royal Marsden Hospital in London, and the Memorial Sloan-Kettering Cancer Center in New York. Dr. Peeters is board member of the Flemish Society of Gastroenterology, chair of the Belgian Group of Digestive Oncology and a member of the Belgian Society of Medical Oncology, the European Society of

Medical Oncology, the American Society for Clinical Oncology and the gastrointestinal group of the European Organisation for Research and Treatment of Cancer. Within EORTC, he is co-chair of the metastatic colorectal task force. His research interests have included the identification of molecular ma

rkers and therapy modulation in digestive tumors. He has been involved in many clinical studies on therapeutic agents for gastrointestinal tumors, published numerous articles in peer reviewed journals and was author of several chapters in oncology books.Lorena Incorvaia is Assistant Professor at the

University Medical School of Palermo (Italy). She is a medical oncologist, PhD in ＂Cellular, Clinical and Molecular Oncopathology＂ from the University of Palermo. Since 2018 is ＂Guest Lecturer＂ at the ＂Department of Molecular Imaging, Pathology, Radiotherapy and Oncology (MIPRO), Faculty of Medicin

e and Health Sciences of the University of Antwerp (Belgium). She is in the national board of Italian Society of Medical Oncology (AIOM), section young oncologist, from 2019. Since April 2020 she is member of the PhD in Experimental Oncology and Surgery at University of Palermo, Department of Surgic

al, Oncological and Oral Sciences, and member of the scientific Italian commission of the 2020 European Horizon Program. She is author of numerous position papers, guidelines and clinical recommendations in the AIOM Group, she is author of several chapters and monographs in oncology books and is act

ually Guest Editor of the ＂Cancers＂ journal. She is co-investigator in several national and international clinical trials and Scientific Director of national and international research projects. She works in collaboration with the ＂Centre de Recherche en Cancérologie de Marseille＂ (CRCM), INSERM-Ma

rseille, France and is actively involved in research studies of immunoncology, molecular biology and cancer genetics, focused on molecular mechanisms of targeted therapy and immunotherapy resistance, identification of novel molecules involved in anti-tumor immune response and immunomodulatory mechan

ism of cancer evolution. Her activity in cancer research is showed by several papers published in international, peer-reviewed, high-indexed journals.Christian Rolfo is Director of Thoracic Medical Oncology and Director of Early Clinical Trials at the University of Maryland Marlene and Stewart Green

ebaum Comprehensive Cancer Center (UMGCCC), in Baltimore, Maryland, USA. He is Professor of Medicine at the Division of Oncology at Maryland University, School of Medicine. In addition, he is Professor of Oncology at Antwerp University in the Center for Oncological Research (CORE) in Antwerp, Belgiu

m. He also serves as Visiting Professor in Oncology and as External Expert in PhD Degrees in Clinical Oncology Research at the Medicine and Surgery School, University of Palermo, Italy. He is actively working on drug development and Lung cancer & Mesothelioma treatment. His research is focused in mo

lecular oncology and Immunotherapy and in a pan-tumoral approach, using new techniques in liquid biopsies, specifically in exosome isolation and circulating free tumour DNA. Prof. Rolfo served as an expert member of the Commission for Medicinal Products for Human Use and First in Human Drugs Commiss

ion at the Federal Agency of Health and Medicinal Products from Belgium and external expert for the European Agency of Medicine (EMA). He is member of the educational committee at the International Association for the Study of Lung Cancer (IASLC), served on the membership committee of ESMO, is the c

urrent vice-president of the International Society of Liquid Biopsy (ISLB) and member of the American Society of Clinical Oncology (ASCO), American Society of Clinical Research (AACR) the Oncology Latin-American Association (OLA). He is Editor in Chief of Critical Review in Oncology Hematology; he h

as been a speaker at national and international forums and has published extensively in peer-reviewed journals.

以疾病不確定感理論發展整合性心動健康網路照顧模式提升心房顫動病人因應策略之成效探討

為了解決Lancet oncology的問題，作者謝慧玲 這樣論述：

正文目錄正文目錄『表』目錄 IV『圖』目錄 V『附錄』目錄 VII中文摘要 VIII英文摘要 X第一章 緒論 1 第一節 研究背景、動機及重要性 1 第二節 研究目的 7第二章 文獻查證 8 第一節 心房顫動疾病簡介 8 第二節 疾病不確定感理論 15 第三節 疾病不確定感相關研究 22 第四節 整合性健康網路照顧模式的發展及運用 31第三章 研究架構與假設 36 第一節 研究架構 36 第二節 研究假設 37 第三節 名詞界定 38第四章 研究方法與過程 43 第一節 研究設計 43 第二節 研究對象及場所 45 第三節 研究工具 46

第四節 研究工具之信效度檢定 52 第五節 研究過程 59 第六節 研究倫量 63 第七節 資料處理與統計分析 64第五章 研究結果 66 第一節 心房顫動病人的基本屬性68 第二節 心房顫動病人的症狀困擾、疾病知識、社會支持、疾病不確定感、因應策略及心理困擾之前後測情形 76 第三節 介入「整合性心動健康網路照顧模式」對於心房顫動病人症狀困擾、疾病知識、社會支持、疾病不確定感、因應策略及心理困擾之成效 85第六章 討論 107 第一節 心房顫動病人的基本屬性現況分析 108 第二節 介入「整合性心動健康網路照顧模式」對於改善心房顫動病人症狀困擾之成效 111

第三節 介入「整合性心動健康網路照顧模式」對於改善心房顫動病人疾病知識之成效 113 第四節 介入「整合性心動健康網路照顧模式」對於改善心房顫動病人社會支持之成效 115 第五節 介入「整合性心動健康網路照顧模式」對於改善心房顫動病人疾病不確定感之成效 117 第六節 介入「整合性心動健康網路照顧模式」對於改善心房顫動病人因應策略之成效 119 第七節 介入「整合性心動健康網路照顧模式」對於改善心房顫動病人心理困擾之成效 121 第八節 研究限制 124第七章 結論與建議 125 第一節 結論 125 第二節 建議 127參考文獻 129附錄 141『表』目錄表1. 資料處理

與分析 65表2. 心房顫動病人之人口基本屬性 70表3. 心房顫動病人的疾病特性 74表4. 心房顫動病人症狀困擾、疾病知識、社會支持、疾病不確定感、因應策略及心理困擾之前測與後測結果 83表5. 以 GEE 方法探討整合性心動健康網路照顧模式於心房顫動病人症狀困擾改變之成效 86表6. 以 GEE 方法探討整合性心動健康網路照顧模式於心房顫動病人疾病知識改變之成效 89表7. 以GEE方法探討整合性心動健康網路照顧模式於心房顫動病人社會支持改變之成效 92表8. 以GEE方法探討整合性心動健康網路照顧模式對於心房顫動病人疾病不確定感之改變成效 95表9. 以GEE方法探討整合性心動健康網路

照顧模式對於心房顫動病人因應策略改變之成效 98表10. 以GEE方法探討整合性心動健康網路照顧模式對於心房顫動病人心理困擾改變之成效 103『圖』目錄圖1. 不確定感理論架構 21圖2. 研究架構圖 36圖3. 研究設計 44圖4. 流程圖 67圖5. 兩組在第三版症狀頻率-嚴重程度評估量表之症狀頻率次量表平均分數於前測、後測第一個月、第三個月與第六個月的變化 87圖6. 兩組在心房顫動知識量表平均分數於前測、後測第一個月、第三個月與第六個月的變化 90圖7. 兩組在醫療社會支持量表平均分數於前測、後測第一個月、第三個月與第六個月的變化 93圖8. 兩組在中文版Mishel疾病不確定感量表平

均分數於前測、後測第一個月、第三個月與第六個月的變化 96圖9. 兩組在簡易因應量表之應對因應策略次量表平均分數於前測、後測第一個月、第三個月與第六個月的變化 99圖10. 兩組在簡易因應量表之迴避因應策略次量表平均分數於前測、後測第一個月、第三個月與第六個月的變化 100圖11. 兩組在醫院焦慮憂鬱量表平均分數於前測、後測第一個月、第三個月與第六個月的變化 104圖12. 兩組在醫院焦慮憂鬱量表之焦慮次量表平均分數於前測、後測第一個月、第三個月與第六個月的變化 105圖13. 兩組在醫院焦慮憂鬱量表之憂鬱次量表平均分數於前測、後測第一個月、第三個月與第六個月的變化 106『附錄』目錄附錄一

心房顫動病人基本屬性量表 附錄一附錄二 第三版症狀頻率-嚴重程度評估量表之症狀頻率次量表 附錄二附錄三 心房顫動知識量表 附錄三附錄四 醫療社會支持量表 附錄四附錄五 中文版Mishel疾病不確定感量表 附錄五附錄六 簡易因應量表 附錄六附錄七 醫院憂鬱焦慮量表 附錄七